Avalo Therapeutics, Inc. Common Stock

AVTXNASDAQUSD
16.63 USD
1.13 (6.36%)🟢LIVE (AS OF 03:12 PM EDT)
🟢Market: OPEN
Open?$18.13
High?$18.50
Low?$16.34
Prev. Close?$17.76
Volume?909.0K
Avg. Volume?777.4K
VWAP?$17.49
Rel. Volume?1.17x
Bid / Ask
Bid?$16.49 × 100
Ask?$16.76 × 100
Spread?$0.27
Midpoint?$16.63
Valuation & Ratios
Market Cap?404.7M
Shares Out?22.8M
Float?14.5M
Float %?78.3%
P/E Ratio?N/A
P/B Ratio?4.42
EPS?-$4.38
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?14.27Strong
Quick Ratio?14.27Strong
Cash Ratio?3.38Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUED
Score
58/100
P/E?
N/A
P/B?
4.42FAIR
P/S?
2,107.93HIGH
P/FCF?
N/A
EV/EBITDA?
-5.7CHEAP
EV/Sales?
1,967.50HIGH
Returns & Efficiency
ROE?
-108.9%WEAK
ROA?
-79.7%WEAK
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$377.8M
Related Companies
Loading...
News
Profile
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
Employees
33
Market Cap
404.7M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2015-11-13
Address
1500 LIBERTY RIDGE DRIVE
WAYNE, PA 19087
Phone: 410-522-8707